News
Company statement
Fri, 05 Dec 2025 18:05:00 -0500
Fri, 05 Dec 2025 18:05:00 -0500
Novo Nordisk warns consumers about counterfeit Ozempic® (semaglutide) injection 1 mg in the US
- FDA seized dozens of units of counterfeit Ozempic® (semaglutide) injection 1 mg distributed illegally outside the Novo Nordisk authorized supply chain
- Visual examination of the seized product contains counterfeit features; product composition has not been conclusively determined at this time
- Novo Nordisk is assisting with the investigation
PLAINSBORO, NJ, December 5, 2025 - FDA recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg distributed illegally outside of Novo Nordisk’s authorized supply chain. The US Food and Drug Administration (FDA) has also updated its website with information about these counterfeit versions of Ozempic.
The counterfeit products labelled with lot number PAR1229 can be identified by the placement of the “EXP/LOT” text on the pen’s label:
 |
Lot number PAR1229 is an authentic lot number. Only when both the lot number is coupled with the above information, is it counterfeit and should not be used. Any product with this lot number obtained through the Novo Nordisk Patient Assistance Program is authentic, genuine Ozempic® 1 mg, and is not counterfeit.
Further analyses will be conducted, including extensive visual examination and planned chemical testing of the seized product. Accordingly, neither Novo Nordisk nor the FDA can confirm the contents or quality of the counterfeit product, which may present a safety risk for patients who use the counterfeit product.
WHAT TO DO: GUIDANCE FOR RETAILERS AND CONSUMERS
Retail pharmacies are advised to purchase authentic Ozempic® (semaglutide) injection 1 mg and other semaglutide-containing medicines through authorized distributors of Novo Nordisk. Pharmacies are encouraged to review the photographs and information provided above. If there are any concerns about whether your batches are authentic, please call Novo Nordisk customer care at 1-800-727-6500 Monday through Friday from 8:30 AM to 6:00 PM EST.
Patients should double-check their Ozempic® box to see if it has lot number PAR1229 and the above information. These products are deemed counterfeit and should not be used. It is important to note that lot number PAR1229 is an authentic lot number. It is a counterfeit product only when that lot number is accompanied by the above information.
Patients are encouraged to only acquire authentic Novo Nordisk Ozempic® (semaglutide) injection 1 mg through state-licensed pharmacies and to check the product for any signs of counterfeiting before using.
- If a prescription is filled via a legitimate retailer who uses our authorized distributors, Novo Nordisk believes the risk of receiving counterfeit medicine is minimized. Patients should check the batch number of the product as described above and below.
- If you are in possession of suspected counterfeit product, you are highly encouraged to:
- Report suspicious Ozempic® product with lot number PAR1229 and the above information or other suspected Novo Nordisk counterfeit products, or if patients need additional help determining if a Novo Nordisk product is counterfeit, please call Novo Nordisk customer care at 1-800-727-6500 Monday through Friday from 8:30 AM to 6:00 PM EST.
- Report it directly to the FDA: Report Suspected Criminal Activity (fda.gov).
- Report any side effect to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program (1-800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, using the same customer care number (1-800-727-6500).
Websites selling counterfeit and/or tampered medicines should be reported to the FDA. Suspected counterfeit products may be reported to the FDA by calling your local FDA consumer complaint coordinator or by reporting it directly at Report Suspected Criminal Activity (fda.gov).
Learn more about the responsible use of semaglutide-containing medicines, how to spot counterfeit products and the significant safety and health risks associated with compounded or knock-off "semaglutide" at www.semaglutide.com.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people across more than 10 manufacturing, R&D and corporate locations in eight states plus Washington, D.C. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.
Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines, which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at semaglutide.com.
Contacts for further information
|
Media: |
|
|
Liz Skrbkova (US)
|
Ambre James-Brown (Global)
|
|
Investors: |
|
|
Frederik Taylor Pitter (US) +1 609 613 0568
|
Jacob Martin Wiborg Rode (Global)
|
|
Sina Meyer (Global) +45 3079 6656
|
Ida Schaap Melvold (Global) +45 3077 5649
|
|
Max Ung (Global)
|
|